Successful retreatment with infliximab in patients with prior severe infusion reactions

Clin Rheumatol. 2006 Jul;25(4):540-1. doi: 10.1007/s10067-005-0029-9. Epub 2005 Oct 7.


Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab can be associated with the development of severe infusion reactions (IR) during retreatment. We present the case of two rheumatoid arthritis patients with a history of severe acute IR to infliximab who subsequently underwent successful infusion using a prophylactic treatment with a combination of H1 and H2 receptor blockers, hydrocortisone, and diphenhydramine.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Diphenhydramine / therapeutic use*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Histamine H1 Antagonists / therapeutic use*
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Hydrocortisone / therapeutic use*
  • Infliximab
  • Infusions, Intravenous / adverse effects
  • Retreatment / methods
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Histamine H1 Antagonists
  • Histamine H2 Antagonists
  • Diphenhydramine
  • Infliximab
  • Hydrocortisone